Mario Venza

Dr. Mario Venza

Department of BIOMORF, University of Messina, Messina 98122, Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
IVIsabella Venza
Isabella Venza
MVMario Venza
Mario Venza
MVMaria Visalli
Maria Visalli
GLGermana Lentini
Germana Lentini
DTDiana Teti
Diana Teti
FDFrancesco Stagno D'Alcontres
Francesco Stagno D'Alcontres
In this review, we examine the multiple roles of ROS in the pathogenesis of melanoma, focusing on signal transduction and regulation of gene expression. In recent years, different studies have analyzed the dual role of ROS in regulating the redox system, with both negative and positive consequences on human health, depending on cell concentration of these agents. High ROS levels can result from an altered balance between oxidant generation and intracellular antioxidant activity and can produce harmful effects. In contrast, low amounts of ROS are considered beneficial, since they trigger signaling pathways involved in physiological activities and programmed cell death, with protective effects against melanoma. Here, we examine these beneficial roles, which could have interesting implications in melanoma treatment.

1 September 2018 in International Immunopharmacology
Verified
Journal Article
Closed access
IVIsabella Venza
Isabella Venza
MVMaria Visalli
Maria Visalli
RORosaria Oteri
Rosaria Oteri
CBConcetta Beninati
Concetta Beninati
DTDiana Teti
Diana Teti
MVMario Venza
Mario Venza

30 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Maria CaffoMaria Caffo
Maria Caffo
ACAntonello Curcio
Antonello Curcio
KRKumar Rajiv
Kumar Rajiv
GCGerardo Caruso
Gerardo Caruso
MVMario Venza
Mario Venza
AGAntonino Germanò
Antonino Germanò
Malignant gliomas are the most common primary brain tumors in adults up to an extent of 78% of all primary malignant brain tumors. However, total surgical resection is almost unachievable due to the considerable infiltrative ability of glial cells. The efficacy of current multimodal therapeutic strategies is, furthermore, limited by the lack of specific therapies against malignant cells, and, therefore, the prognosis of these in patients is still very unfavorable. The limitations of conventional therapies, which may result from inefficient delivery of the therapeutic or contrast agent to brain tumors, are major reasons for this unsolved clinical problem. The major problem in brain drug delivery is the presence of the blood–brain barrier, which limits the delivery of many chemotherapeutic agents. Nanoparticles, thanks to their chemical configuration, are able to go through the blood–brain barrier carrying drugs or genes targeted against gliomas. Carbon nanomaterials show distinct properties including electronic properties, a penetrating capability on the cell membrane, high drug-loading and pH-dependent therapeutic unloading capacities, thermal properties, a large surface area, and easy modification with molecules, which render them as suitable candidates for deliver drugs. In this review, we will focus on the potential effectiveness of the use of carbon nanomaterials in the treatment of malignant gliomas and discuss the current progress of in vitro and in vivo researches of carbon nanomaterials-based drug delivery to brain.


1 December 2025 in PLASTIC RECONSTRUCTIVE & REGENERATIVE SURGERY
Verified
Journal Article
Open access
PDF file
MVMario Venza
Mario Venza
GIGiuseppe Iatì
Giuseppe Iatì
IVIsabella Venza
Isabella Venza
MBMassimiliano Berretta
Massimiliano Berretta
APAntonio Pontoriero
Antonio Pontoriero
Background. The choice between Autologous Tissue Breast Reconstruction (ABR) and Implant-Based Reconstruction (IBR) is a fundamental decision in breast cancer survivorship. This choice is influenced by surgical evolution – specifically the shift to muscle-sparing techniques – and a modern focus on Patient-Reported Outcomes (PROs). This review critically compares these two modalities, focusing on long-term satisfaction, functional morbidity, and the definitive impact of radiotherapy (RT).Methods. A structured literature review was conducted in accordance with PRISMA principles, utilizing MEDLINE and Embase databases from January 2015 to September 2025. The search strategy combined MeSH terms for “Mammaplasty”, “Patient Reported Outcome Measures” (BREAST-Q), and “Radiotherapy”. We prioritized systematic reviews, meta-analyses, and large comparative cohort studies (n = 60) that provided objective complication rates and subjective outcomes in both irradiated and non-irradiated settings.Results. Evidence confirms that ABR provides statistically superior longterm satisfaction, psychosocial well-being, and sexual well-being 1-3. This is driven by its biological integration and “like-with-like” properties. Conversely, IBR carries a high cumulative burden of re-operation (> 50% at 10 years) due to capsular contracture and aesthetic failure 4. Most critically, RT is the dominant predictor of failure, causing IBR failure rates exceeding 30%, whereas vascularized ABR flaps demonstrate robust resilience 5,6.Conclusions. While modern pre-pectoral IBR is a viable, low-morbidity option for select non-irradiated patients, ABR provides the most durable and psychologically favorable long-term outcome. The anticipated need for post-mastectomy radiation must be the primary driver in clinical decision-making, favoring autologous reconstruction as the gold standard in the irradiated setting.